0 429

Cited 2 times in

First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma

DC Field Value Language
dc.contributor.author장지석-
dc.contributor.author김경환-
dc.contributor.author신상준-
dc.contributor.author금웅섭-
dc.contributor.author정기양-
dc.contributor.author노미령-
dc.contributor.author김상겸-
dc.contributor.author정민규-
dc.contributor.author김규현-
dc.date.accessioned2022-12-22T05:10:43Z-
dc.date.available2022-12-22T05:10:43Z-
dc.date.issued2022-11-
dc.identifier.issn0190-9622-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/192325-
dc.description.abstractBackground: Limited data are available to assist the selection between immune checkpoint inhibitors and BRAF/mitogen-activated protein kinase kinase inhibitors as first-line treatment for patients with BRAF-mutant advanced malignant melanoma. Objective: To investigate the outcomes associated with first-line pembrolizumab or dabrafenib/trametinib treatment for advanced melanoma with activating BRAF V600 mutation. Methods: Data of patients with BRAF V600-mutant melanoma who were treated with first-line pembrolizumab (n = 40) or dabrafenib/trametinib (n = 32) were analyzed. Tumor response, progression-free survival, and overall survival were evaluated. Immune evasion accompanied with emerging resistance to BRAF/mitogen-activated protein kinase kinase inhibitors was assessed. Results: A longer overall survival was observed after first-line pembrolizumab treatment than after first-line dabrafenib/trametinib treatment (hazard ratio = 2.910, 95% CI: 1.552-5.459), although there were no significant differences in progression-free survival (P = .375) and response rate (P = .123). Emergence of resistance to dabrafenib/trametinib co-occurred with immune evasion, enabling melanoma cells to escape recognition and killing by Melan-A-specific CD8+ T cells. Limitations: Analysis was conducted in a retrospective manner. Conclusion: Pembrolizumab may be recommended over BRAF/mitogen-activated protein kinase kinase inhibitors as the first-line treatment in patients with advanced BRAF V600-mutant melanoma.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherMosby-
dc.relation.isPartOfJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / therapeutic use-
dc.subject.MESHCD8-Positive T-Lymphocytes / pathology-
dc.subject.MESHHumans-
dc.subject.MESHImidazoles-
dc.subject.MESHImmune Checkpoint Inhibitors-
dc.subject.MESHMART-1 Antigen-
dc.subject.MESHMelanoma* / drug therapy-
dc.subject.MESHMelanoma* / genetics-
dc.subject.MESHMelanoma* / pathology-
dc.subject.MESHMitogen-Activated Protein Kinase Kinases-
dc.subject.MESHMutation-
dc.subject.MESHOximes / therapeutic use-
dc.subject.MESHProtein Kinase Inhibitors / therapeutic use-
dc.subject.MESHProto-Oncogene Proteins B-raf / genetics-
dc.subject.MESHPyridones / adverse effects-
dc.subject.MESHPyrimidinones-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSkin Neoplasms* / drug therapy-
dc.subject.MESHSkin Neoplasms* / genetics-
dc.subject.MESHSkin Neoplasms* / pathology-
dc.titleFirst-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorChang Gon Kim-
dc.contributor.googleauthorMiso Kim-
dc.contributor.googleauthorJieon Hwang-
dc.contributor.googleauthorSeung Tae Kim-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorKyoo Hyun Kim-
dc.contributor.googleauthorKyung Hwan Kim-
dc.contributor.googleauthorJee Suk Chang-
dc.contributor.googleauthorWoong Sub Koom-
dc.contributor.googleauthorMi Ryung Roh-
dc.contributor.googleauthorKee Yang Chung-
dc.contributor.googleauthorTae Min Kim-
dc.contributor.googleauthorSang Kyum Kim-
dc.contributor.googleauthorJeeyun Lee-
dc.contributor.googleauthorSang Joon Shin-
dc.identifier.doi10.1016/j.jaad.2022.07.057-
dc.contributor.localIdA04658-
dc.contributor.localIdA05226-
dc.contributor.localIdA02105-
dc.contributor.localIdA00273-
dc.contributor.localIdA03582-
dc.contributor.localIdA01278-
dc.contributor.localIdA00520-
dc.relation.journalcodeJ01766-
dc.identifier.eissn1097-6787-
dc.identifier.pmid36068115-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0190962222024434?via%3Dihub-
dc.subject.keywordBRAF V600–mutant advanced melanoma-
dc.subject.keyworddabrafenib/trametinib-
dc.subject.keywordfirst-line treatment-
dc.subject.keywordpembrolizumab-
dc.contributor.alternativeNameChang, Jee Suk-
dc.contributor.affiliatedAuthor장지석-
dc.contributor.affiliatedAuthor김경환-
dc.contributor.affiliatedAuthor신상준-
dc.contributor.affiliatedAuthor금웅섭-
dc.contributor.affiliatedAuthor정기양-
dc.contributor.affiliatedAuthor노미령-
dc.contributor.affiliatedAuthor김상겸-
dc.citation.volume87-
dc.citation.number5-
dc.citation.startPage989-
dc.citation.endPage996-
dc.identifier.bibliographicCitationJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol.87(5) : 989-996, 2022-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.